European Parliament Lead on Clinical Trials Regulation gets tough on transparency
This article was originally published in Scrip
Executive Summary
The lead legislator on the proposed Clinical Trials Regulation at the European Parliament has called for major transparency-related changes to be made to the draft legislation. Glenis Willmott has suggested, among other things, that the proposed text of the CTR be amended to clarify that "clinical trial data should not be considered commercially confidential once a marketing authorization has been obtained [by a drug company]".
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.